Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

Phase 3LAM561Positive

AI Analysis

Summary

Laminar Pharma announced completion of patient enrollment in its Phase 2b/3 trial of LAM561 for newly diagnosed glioblastoma. The achievement of last patient, last visit represents a key milestone toward potential data readout and regulatory submission.

Clinical Trial Data

Phase

2b/3

Outcome Details

Last patient, last visit completed in Phase 2b/3 trial

Importance:6/10

Sentiment:

0.60

glioblastomaPhase 2b/3clinical trialLPLVmembrane lipid therapy

Read the original article

Published by PR Newswire Biotech on July 24, 2026 1:30 AM

Read Original